The accessibility and affordability of biologics and biosimilars are greatly influenced by the dynamics and pricing differences within the prescription drug supply chain. These factors can impede the adoption of biosimilars, leading to reduced competition and fewer cost savings for patients and healthcare systems. Ross Day, RPH, DP, former Director of Pharmacy at Vizient and current pharmaceutical consultant, and Antonio Ciaccia, CEO and co-founder of 46brooklyn, President of 3 Axis Advisors, will explore the dynamics of the prescription drug supply chain and pricing disparities related explicitly to biologics and biosimilars during this panel discussion.
• Gain comprehensive insight into the profound impact of prescription drug chain dynamics and pricing disparities on the accessibility and affordability of biologics and biosimilars
• Explore the intricacies surrounding barriers to biosimilar adoption and their far-reaching effects on market competition
• Engage in meaningful discussions to devise effective strategies for mitigating pricing disparities, enhancing access to biologics and biosimilars, and realizing substantial cost savings for patients and healthcare systems